Measurable/minimal residual disease monitoring by next-generation sequencing in patients with acute myeloid leukemia

Next-generation sequencing (NGS) has been applied to measurable/minimal residual disease (MRD) monitoring after induction chemotherapy in acute myeloid leukemia (AML) patients, but the optimal time point for the test remains unclear. In this study, we aimed to investigate the clinical significance of NGS MRD at two different time points. We performed targeted NGS of 54 genes in bone marrow cells serially obtained at diagnosis, first complete remission (1st time point), and after the first consolidation chemotherapy (2nd time point). The patients with detectable NGS MRD at either time point had a significantly higher cumulative incidence of relapse, shorter relapse-free survival and overall survival. In multivariate analysis, the MRD1st and MRD2nd were both independent poor prognostic factors. However, the patients with positive MRD1st but negative MRD2nd had a similar good prognosis to those with negative MRD at both time points. The incorporation of multiparameter flow cytometry and NGS MRD revealed that the presence of NGS MRD predicted poorer prognosis among the patients without detectable MRD by multiparameter flow cytometry at the second time point, but not the first time point. In conclusion, the presence of NGS MRD, especially after the first consolidation therapy, can help predict the clinical outcome of AML patients.